Perrett, Kirsten P <br/><br/>
Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.  [electronic resource] 

 -  Vaccine  Sep 2015 
 - 5217-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2518 
<br/><br/><label>Standard No.: </label>10.1016/j.vaccine.2015.06.103  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antibodies, Bacterial--blood<br/>Antigens, Bacterial--immunology<br/>Australia<br/>Blood Bactericidal Activity<br/>Canada<br/>Child<br/>Complement System Proteins<br/>Drug-Related Side Effects and Adverse Reactions--epidemiology<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Immunization Schedule<br/>Male<br/>Meningococcal Infections--immunology<br/>Meningococcal Vaccines--administration & dosage<br/>Neisseria meningitidis, Serogroup B--immunology<br/>Treatment Outcome